Apixaban in non-valvular atrial fibrillation and treatment of venous thromboembolism: universal safety advantage in different categories of patients
This review presents data on the frequency of bleeding in direct comparison of apixaban and vitamin K antagonists in the context of prospective randomized controlled trials. According to ARISTOTLE, AUGUSTUS and AMPLIFY studies, Apixaban has an advantage over vitamin K antagonists in terms of safety...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2020-10-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5811 |